Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cubicin clears FDA

Executive Summary

Cubist's Cubicin, formerly Cidecin (daptomycin for injection) is approved Sept. 12 for treatment of complicated skin and skin structure infections. An FDA "Talk Paper" notes it is the first cyclic lipopeptide antibacterial agent. Cubicin's priority action review date of June 20 had been extended three months after reformatting of data sets (1"The Pink Sheet" June 23, 2003, In Brief)...

You may also be interested in...

Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers

Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said

Chiron Tifacogin Needs One Pivotal Study For Community Acquired Pneumonia

Chiron will need only a single pivotal trial for approval of its tissue factor pathway inhibitor tifacogin as a treatment for severe community acquired pneumonia

Cubist Cubicin Marketing To Highlight Single Daily Dose Of Antibiotic

Cubist's Cubicin (daptomycin) will be promoted for its single daily dosing compared to traditional antibiotics administered at least twice daily

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts